<DOC>
	<DOCNO>NCT01265810</DOCNO>
	<brief_summary>Targeted therapy multi-targeted tyrosine kinase inhibitor ( TKI ) mammalian target rapamycin inhibitor ( mTORI ) renal cell carcinoma ( RCC ) , demonstrate high level efficacy acceptable tolerability . Currently , five approve targeted therapy available RCC : sunitinib ( Sutent® ) , sorafenib ( Nexavar® ) , pazopanib ( Votrient® ) , temsirolimus ( Torisel® ) , everolimus ( Afinitor® ) . Hepatocellular carcinoma treat sorafenib gastro intestinal stromal tumor patient treat sunitinib include , . Since agent dermatological adverse event common , oral mucositis ( OM ) , hand-foot skin reaction ( HFSR ) papulopustular eruption ( PPE ) disable side effect , require evidence base management option prevent treat adverse event . The incidence OM grade sunitinib 38 % , sorafenib 28 % , pazopanib 4 % , temsirolimus 41 % , everolimus 44 % . Recent data suggest TKI mTORI associate OM distinct conventional mucositis closely resemble aphthous OM . Recently , supersaturated calcium-phosphate rinse ( Caphosol® ) , Ca2+/PO43- mouth rinse , become available prevent treat OM . The objective ass relieve effect Caphosol® oral rinse clinical outcome include oral intake , swallow function pain associate incidence grade ≥ 1 oral side effect anticancer therapy cessation patient treat select targeted anticancer therapy . Patients OM &gt; grade 0 targeted therapy randomly allocate receive either Caphosol® NaCl 0.9 % rinse two week . After first rinse period patient switch opposite treatment arm ( NaCl 0.9 % Caphosol® ) another two week . Duration oral side effect , severity , pain , dose analgesic tolerability assess weekly VHNSS oral-specific questionnaire . Patients stratify targeted anticancer agent per tumor type ( pre-defined cohort ) . Objective severity oral side effect assess use NCI-CTCAE v4.0 . Correlation subjective VHNSS score objective NCI-CTCAE grade , sex , age , target therapy type , cancer type conduct .</brief_summary>
	<brief_title>Caphosol Oral Mucositis Due Targeted Therapy</brief_title>
	<detailed_description>OM mucosal change , associate pain , taste change - clinically relevant toxicity TKI 's mTORI 's presently use . The incidence oral mucositis grade sunitinib 38 % , sorafenib 28 % , pazopanib 4 % , temsirolimus 41 % , everolimus 44 % . Optimal antitumor activity require maintain high tolerable dose individual patient . In order improve health relate quality life ( HRQoL ) patient adherence , adverse effect prevent , possible avoid treated necessary . Current oral formulation consist various schedule ( continuous administration 4 week , 2 week ) optimize benefit-risk profile . Adherence anti-cancer treatment particularly important prescribe oral therapy adherence protocol significant impact efficacy severity treatment-related AEs . As sorafenib , sunitinib , pazopanib , everolimus take outpatient setting , patient education correct treatment dosing , usage nature , recognition , severity AEs essential . Recent data suggest TKI mTORI associate OM different conventional chemotherapy relate OM . Oral ulceration usually present aphthous-like ulceration study report mucositis . An analysis appearance , course , toxicity experience demonstrate condition distinct conventional mucositis closely resemble aphthous oral mucositis . These TKI/mTORI relate ulcer may represent dose-limiting toxicity new class agent , especially consider fact even low grade mucositis chronic daily dosing may cumbersome patient lead dose reduction . Studies treatment strategy aphthous OM may therefore important dose adherence TKI mTORI overall acceptance therapy patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Male female subject ≥18 year age Histological proof RCC , HCC GIST Oral adverse event &gt; grade 0 due sunitinib , sorafenib , pazopanib , temsirolimus , everolimus mono therapy study entry Written inform consent Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Able perform oral rinse Able complete questionnaire assistance Any previous systemic antineoplastic treatment within 4 week initiation current targeted anticancer therapy Current antineoplastic combination cytotoxic chemotherapy therapy Physiologic condition precludes use oral rinse Hypersensitivity Caphosol ingredient Use palifermin , oral cryotherapy , low level laser therapy , topical oral steroid within 3 week current targeted anticancer therapy Oral abnormality define baseline oral assessment NCICTCAE v4.0 grade &gt; 0 Current use agent know strong inducer inhibitor CYP3A4 stop</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oral mucositis</keyword>
	<keyword>target therapy</keyword>
	<keyword>Caphosol</keyword>
	<keyword>management</keyword>
</DOC>